1.	Phase I/II Study of Adjuvant Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides in Patients Who Have Undergone Lymphadenectomy for Stage III Melanoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MSCMI-21/01/02, MSCMCC 21/01/02, EU-21006, NCT01082198
2.	Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: LYMNHL0040, 96940, LYMNHL0040-BMT212, NCT00490529
3.	Ovarian Dendritic Cell Vaccine Trial Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 200541, NCT00703105